Efficient synthesis of functional isoprenoids from acetoacetate through metabolic pathway-engineered Escherichia coli

被引:63
作者
Harada, Hisashi [1 ]
Yu, Fengnian [2 ]
Okamoto, Sho [2 ]
Kuzuyama, Tomohisa [3 ]
Utsumi, Ryutaro [2 ]
Misawa, Norihiko [1 ]
机构
[1] Kirin Holdings Co Ltd, Cent Labs Frontier Technol, iBIRD 3 570, Nonoichi, Ishikawa 9218836, Japan
[2] Kinki Univ, Grad Sch Agr, Dept Biosci, Nara 6318505, Japan
[3] Univ Tokyo, Biotechnol Res Ctr, Lab Cell Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan
关键词
alpha-Humulene; Lycopene; Astaxanthin; Sesquiterpene; Carotenoids; ASTAXANTHIN BIOSYNTHETIC-PATHWAY; ZINGIBER-ZERUMBET SMITH; SP STRAIN CL190; ISOPENTENYL DIPHOSPHATE; COA SYNTHETASE; BETA-CAROTENE; GENE-CLUSTER; MEVALONATE PATHWAY; LYCOPENE BIOSYNTHESIS; METHYLOMONAS SP;
D O I
10.1007/s00253-008-1724-7
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We show here an efficient synthesis system of isoprenoids from acetoacetate as the main substrate. We expressed in Escherichia coli a Streptomyces mevalonate pathway gene cluster starting from HMG-CoA synthase and including isopentenyl diphosphate isomerase (idi) type 2 gene and the yeast idi type 1 and rat acetoacetate-CoA ligase (Aacl) genes. When the alpha-humulene synthase (ZSS1) gene of shampoo ginger was expressed in this transformant, the resultant E. coli produced 958 mu g/mL culture of alpha-humulene with a lithium acetoacetate (LAA) supplement, which was a 13.6-fold increase compared with a control E. coli strain expressing only ZSS1. Next, we investigated if this E. coli strain engineered to utilize acetoacetate can synthesize carotenoids effectively. When the crtE, crtB, and crtI genes required for lycopene synthesis were expressed in the transformant, lycopene amounts reached 12.5 mg/g dry cell weight with addition of LAA, an 11.8-fold increase compared with a control expressing only the three crt genes. As for astaxanthin production with the E. coli transformant, in which the crtE, crtB, crtI, crtY, crtZ, and crtW genes were expressed, the total amount of carotenoids produced (astaxanthin, lycopene, and phytoene) was significantly increased to 7.5 times that of a control expressing only the six crt genes.
引用
收藏
页码:915 / 925
页数:11
相关论文
共 44 条
  • [1] Metabolic engineering of the terpenoid biosynthetic pathway of Escherichia coli for production of the carotenoids β-carotene and zeaxanthin
    Albrecht, M
    Misawa, N
    Sandmann, G
    [J]. BIOTECHNOLOGY LETTERS, 1999, 21 (09) : 791 - 795
  • [2] Identifying gene targets for the metabolic engineering of lycopene biosynthesis in Escherichia coli
    Alper, H
    Jin, YS
    Moxley, JF
    Stephanopoulos, G
    [J]. METABOLIC ENGINEERING, 2005, 7 (03) : 155 - 164
  • [3] Construction of lycopene-overproducing E-coli strains by combining systematic and combinatorial gene knockout targets
    Alper, H
    Miyaoku, K
    Stephanopoulos, G
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (05) : 612 - 616
  • [4] A RADIOCHEMICAL ASSAY FOR ACETOACETYL-COA SYNTHETASE
    BERGSTROM, JD
    EDMOND, J
    [J]. ANALYTICAL BIOCHEMISTRY, 1985, 149 (02) : 358 - 364
  • [5] Britton G., 2001, Carotenoids Handbook
  • [6] Requirement for the enzymes acetoacetyl coenzyme A synthetase and poly-3-hydroxybutyrate (PHB) synthase for growth of Sinorhizobium meliloti on PHB cycle intermediates
    Cai, GQ
    Driscoll, BT
    Charles, TC
    [J]. JOURNAL OF BACTERIOLOGY, 2000, 182 (08) : 2113 - 2118
  • [7] Production of isoprenoid pharmaceuticals by engineered microbes
    Chang, Michelle C. Y.
    Keasling, Jay D.
    [J]. NATURE CHEMICAL BIOLOGY, 2006, 2 (12) : 674 - 681
  • [8] Characterization of β-carotene ketolases, CrtW, from marine bacteria by complementation analysis in Escherichia coli
    Choi, SK
    Nishida, Y
    Matsuda, S
    Adachi, K
    Kasai, H
    Peng, X
    Komemushi, S
    Miki, W
    Misawa, N
    [J]. MARINE BIOTECHNOLOGY, 2005, 7 (05) : 515 - 522
  • [9] Connolly J.D., 1991, DICT TERPENOIDS
  • [10] Cragg GM, 1998, MED RES REV, V18, P315, DOI 10.1002/(SICI)1098-1128(199809)18:5<315::AID-MED3>3.3.CO